---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000007"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:56:41.994754+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio FY2023 net loss $73.3M, revenue drops to $0.8M, cash down to $142.1M

## Summary
- Net loss of $73.3M ($1.91 per share) vs net income of $5.3M in 2022; revenue fell to $0.8M from $44.7M on lower Vaxzevria royalties.
- Cash and equivalents $142.1M at Dec 31, 2023, down from $194.4M; operating cash burn $50.9M.
- R&D expenses rose to $44.9M (+$2.5M); G&A surged to $39.8M (+$33.4M) primarily due to a $7.6M foreign exchange loss.
- Pipeline: positive HBV VTP-300 Phase 2 data; HPV VTP-200 APOLLO trial final results expected Q2 2024; celiac VTP-1000 Phase 1 initiation planned Q2 2024.
- Secured up to $35M from CEPI for MERS candidate VTP-500; renamed from Vaccitech to Barinthus in Nov 2023.

## SEC filing metadata
- accession: 0001828185-24-000007
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/0001828185-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/brns-20240320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000007
- JSON: https://secwatch.observer/filing/0001828185-24-000007.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000007.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported the year ended December 31, 2023 results: revenue $0.8 million, net income net loss of $73.4 million.
  - Period: the year ended December 31, 2023
  - Revenue: $0.8 million
  - Net income: net loss of $73.4 million
  - Result: reported results
  source text: • Cash position: As of December 31, 2023, cash was $142.1 million, compared to $194.4 million as of December 31, 2022. The cash used in operating activities was $50.9 million, primarily resulting from our net loss of $73.4 million, adjusted by foreign exchange loss on translation of $7.5 million, share-based compensation of $5.1 million, depreciation and amortization of $5.4 million, deferred tax movements of $3.1 million and changes in our operating assets and liabilities, net of $6.2 million primarily related to a $5.8 million decrease in accounts receivable, a $2.2 million decrease in prepaid expenses and other current assets, $3.4 million decrease in accounts payable and $2.0 million increase in accrued expenses. • Revenue: Revenue was $0.8 million in 2023 compared to $44.7 million in 2022 and was comprised of the Company’s share of royalties received by Oxford University Innovation as a result of commercial sales of Vaxzevria® by AstraZeneca, sales of which reduced significantly i
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/0001828185-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.